Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Inderide-40/25, Inderide-80/25, Inderide La 80/50, Inderide La 120/50, Inderide La 160/50. Every FDA application for this active ingredient: 2 branded and 17 generic. Boxed warning
As of Nov 22, 2026, FDA lists 19 applications for Hydrochlorothiazide; Propranolol hydrochloride (sold as Inderide-40/25, Inderide-80/25, Inderide La 80/50 and others), first approved Jun 15, 1979, with 1 new use approved and 0 published complete response letters.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Hydrochlorothiazide
$24.4M for 3,096,285 prescriptions, −13% on 2024
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA